Find information on Industry Analysis Report

Posts tagged ‘Cardiovascular’

Endo Partnering 2005-2012

The Partnering Agreements with Endo report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
This report provides all the information you require to better understand Eli Lilly and its partnering interests and activities over the past five years.
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.
http://www.bharatbook.com/healthcare-market-research-reports/endo-partnering-2005-2012.html

Description
This report provides all the information you require to better understand Endo and its partnering interests and activities over the past seven years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

For more information kindly visit :
Endo Partnering 2005-2012

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://in.linkedin.com/in/bharatbook
http://healthcareraj.blogspot.com/

Diabetes Partnering 2007-2012

The Diabetes Partnering 2007-2012 report provides understanding and access to the diabetes partnering deals and agreements entered into by the worlds leading healthcare companies.
* Trends in diabetes partnering deals
* Top diabetes deals by value
* Deals listed by company A-Z, industry sector, stage of development, technology type

Description
The Diabetes Partnering 2007-2012 provides understanding and access to the diabetes partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of diabetes partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diabetes technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 500 links to online copies of actual diabetes deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of diabetes partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diabetes partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading diabetes deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of diabetes partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of diabetes technologies and products.

Report scope
Diabetes Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to diabetes trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:
Trends in diabetes dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
The leading diabetes deals by value since 2007

In Diabetes Partnering 2007-2012, the available deals are listed by:
* Headline value
* Upfront payment value
* Royalty rate value
* Company A-Z
* Industry sector
* Stage of development at signing
* Deal component type
* Technology type

For more information kindly visit :
Diabetes Partnering 2007-2012

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://in.linkedin.com/in/bharatbook
http://healthcareraj.blogspot.com/

Aspen Partnering 2005-2012

The Partnering Agreements with Aspen report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
This report provides all the information you require to better understand Apotex and its partnering interests and activities over the past five years.
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

Description
This report provides all the information you require to better understand Aspen and its partnering interests and activities over the past seven years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

For more information kindly visit :
Aspen Partnering 2005-2012

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://in.linkedin.com/in/bharatbook
http://healthcareraj.blogspot.com/

Actelion Partnering 2005-2012

The Partnering Agreements with Actelion report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
This report provides all the information you require to better understand Actavis and its partnering interests and activities over the past five years.
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

Description
This report provides all the information you require to better understand Actelion and its partnering interests and activities over the past seven years.

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2010 pharmaceutical revenues and their respective partnering activity. Chapter 3 provides an overview of the leading partnering and M&A 2005 to present date based on headline value.

Chapter 4 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

The main body of the report is provided in chapter 6. A profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, partnering interests, partnering activity according to deal type, industry sector, phase of development, and therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the user with the tools to make successful contact with the right partners effectively and efficiently.

For more information kindly visit :
Actelion Partnering 2005-2012

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://in.linkedin.com/in/bharatbook
http://healthcareraj.blogspot.com/

Cardiovascular Devices Market in Emerging Economies – Increasing Incidence

“Cardiovascular Devices Market in Emerging Economies (India, China and Brazil) – Increasing Incidence of Cardiovascular Diseases and Lifestyle Disorders to Drive the market” provides information and analysis on the cardiovascular devices market in the emerging countries namely-China, India and Brazil. The report provides market landscape, competitive landscape and market trends information on cardiac rhythm management devices, external defibrillator market, Interventional cardiology, peripheral vascular devices, cardiovascular prosthetic devices, cardiac assist devices, cardiovascular surgery, electrophysiology, cardiovascular monitoring and diagnostic devices in the emerging countries. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape and the profiles of companies operating in these geographies.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope
– Key geographies covered include the China, India and Brazil.
– The categories included are cardiac rhythm management devices, external defibrillator market, Interventional cardiology, peripheral vascular devices, cardiovascular prosthetic devices, cardiac assist devices, cardiovascular surgery, electrophysiology, cardiovascular monitoring and diagnostic devices.
– The report includes details about the key drivers and restraints that are shaping the emerging countries cardiovascular devices market. The report also includes company shares of important companies in each category of the emerging countries cardiovascular devices market.
– The report also covers information on the leading market players, the competitive landscape.
– Key players covered include Medtronic, Boston Scientific, St.Jude Medical, Edwards Lifesciences, Abbott Laboratories, Philips Healthcare, Terumo, Zoll Medical, Microport, Lepu Medical. Asahi Intec Co, Fukuda Denshi, Nihon Kohden, Vascular Concepts, Cordis and Sorin.

Reasons to buy
– Develop business strategies by understanding the trends and developments that are driving the emerging countries cardiovascular devices market.
– Design and develop your product development, marketing and sales strategies.
– Capitalize on M&A opportunities by identifying key companies
– Develop market entry and market expansion strategies.
– Identify the key companies that are best positioned to take advantage of emerging market opportunities.
– Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.
– Identify, understand and capitalize on the next big thing in the emerging countries cardiovascular devices market market landscape
– Make more informed business decisions from the insightful and in-depth analysis of the emerging countries cardiovascular devices market and the factors shaping it

Companies Mentioned
Boston Scientific Corporation
Lepu Medical Technology (Beijing) Co.Ltd
Medtronic, Inc
Microport
Terumo Corporation
Abbott
Biosensors International Group
Cordis
St. Jude Medical, Inc.
Sorin Group
ASAHI INTECC CO., LTD. (ASAHI)
C.R. Bard, Inc.
Vascular Concepts Limited
Volcano Corporation
Philips Healthcare
Braile Biomedica
Goodman Co., Ltd.
MAQUET GmbH & Co. KG
ZOLL Medical Corporation.
Eurocor GmbH (Subsidary of Opto Circuits India Ltd
Edwards Lifesciences Corporation
Fukuda Denshi Co. Ltd
Biosense Webster, Inc.
BIOTRONIK SE & Co. KG
Nihon Kohden

For more information kindly visit :
Cardiovascular Devices Market in Emerging Economies – Increasing Incidence

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/Sandhya3B
Our Blogs: http://healthcareraj.blogspot.com/
http://www.facebook.com/pages/Bharat-Book-Bureau/133809389971352

Tag Cloud